Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently ...
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and provided ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果